Stock comparison
BioMarin Pharmaceutical
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMRN
BioMarin Pharmaceutical
Market cap
$10.45B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMRN | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 58D | 75B | IDXX |
| Benjamin Graham | 57D | 80A | IDXX |
| Philip Fisher | 55C | 75B | IDXX |
| Peter Lynch | 47D | 71B | IDXX |
| Joel Greenblatt | 28F | 83C | IDXX |
| Charlie Munger | 45D | 87A | IDXX |
| Terry Smith | 52D | 84A | IDXX |
Side-by-side metrics
| Metric | BMRN | IDXX |
|---|---|---|
| Market cap | $10.45B | $44.12B |
| P/E (TTM) | 38.7x | 39.0x |
| EV/EBIT | 18.1x | 31.6x |
| ROIC (TTM) | 3.92% | 40.66% |
| Gross margin | 75.93% | 62.05% |
| Net margin | 8.29% | 24.63% |
| Revenue CAGR 5y | 14.93% | 7.56% |
| EPS CAGR 5y | 2.29% | 10.79% |
| Debt / Equity | 0.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMRN leads on
- EPS CAGR 5y2.29%vs 10.79%+95%
- Debt / Equity0.2xvs 0.7x+67%
- Revenue CAGR 5y14.93%vs 7.56%+49%
- EV/EBIT18.1xvs 31.6x+43%
IDXX leads on
- ROIC (TTM)40.66%vs 3.92%+90%
- Market cap$44.12Bvs $10.45B+76%
- Net margin24.63%vs 8.29%+66%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.